Health Care Businesses

Three more charged in $80M heist of Lilly drugs

April 23, 2014
Associated Press
Three Florida men who federal authorities say stole about $80 million in prescription drugs from an Eli Lilly and Co. warehouse in Connecticut have been charged with conspiracy and theft.
More

Lilly to pay dearly for Novartis animal health biz

April 22, 2014
J.K. Wall
Wall Street analysts raised their eyebrows at the hefty price Eli Lilly and Co. will pay to acquire Novartis Animal Health, when compared to the value of the biggest player in the field.
More

Lilly wins approval for potential blockbuster drug

April 21, 2014
Bloomberg News
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
More

Indiana insurers must make best guesses on 2015 price hikes

April 10, 2014
J.K. Wall
Health insurers such as WellPoint Inc. that plan to hike prices on their Obamacare policies more than 10 percent in 2015 will have a much harder time than usual making their case to regulators.
More

Lilly stock shows little impact from $3B court award

April 8, 2014
Eli Lilly and Co.’s stock showed little change Tuesday morning in the wake of a federal court decision that saw jurors order the company to pay a massive damage award related to its Actos diabetes medicine.
More

Lilly ordered to pay $3 billion in Actos damages

April 8, 2014
Bloomberg News
Takeda Pharmaceutical Co. and Eli Lilly and Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
More

Pfizer, Lilly drugs slow advanced breast cancer in studies

April 7, 2014
Bloomberg News
Pfizer Inc., Eli Lilly and Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential.
More

Patent ‘troll’ label gets Congress to ponder what’s in a name

April 2, 2014
Bloomberg News
"Troll" is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
More

Would-be Lilly foe wins U.S. panel backing for inhaled insulin

April 1, 2014
Bloomberg News
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
More

Indianapolis court backs patent for Lilly cancer drug Alimta

April 1, 2014
Associated Press
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
More

Cancer treatment makes Endocyte premium takeover target

March 28, 2014
Bloomberg News
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
More

Would-be Lilly competitor's inhaled insulin tied to lung concerns

March 28, 2014
Bloomberg News
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.'s first marketed product. The treatment would compete against Lilly's Humalog. An FDA report tied the drug to a decline in lung function.
More

Lilly CEO got 10-percent pay boost last year

March 24, 2014
J.K. Wall
Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly's proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
More

Bold developer stirs up nursing-home businessRestricted Content

March 22, 2014
J.K. Wall
Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.
More

Lilly diabetes drug wins backing from EU regulator

March 21, 2014
Bloomberg News
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
More

Discovery may be key to Alzheimer's treatment

March 20, 2014
Bloomberg News
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
More

WellPoint getting unexpected competition from co-ops

March 13, 2014
Bloomberg News
Obamacare opponents predicted early on that insurance co-ops created by the law would fail, but several are doing well by combining low premiums with a certain homespun appeal.
More

Purdue-based cancer imaging firm lands $15M in funding

March 11, 2014
J.K. Wall
OnTarget Laboratories LLC's technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
More

Lilly diabetes drug rejected by FDA over manufacturing issue

March 5, 2014
Bloomberg News
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won't be able to sell it until issues are resolved at a German plant.
More

Kentucky's largest health system makes major jobs cut

March 1, 2014
Associated Press
Hospital company KentuckyOne Health, which employs more than 14,000 people in Kentucky and southern Indiana, says it has laid off about 500 people.
More

Lilly diabetes drug matches competitors' effectiveness

February 25, 2014
 IBJ Staff and Bloomberg News
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
More

Lilly acquires animal health business, lowers forecast

February 24, 2014
 Associated Press and IBJ Staff
Eli Lilly and Co. is buying a privately held, poultry-vaccine maker based in Germany to strengthen its Elanco animal health subsidiary.
More

Lilly drug shows promise as lung cancer treatment

February 19, 2014
J.K. Wall
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
More

Deals up, dollars down in 2013 for Indiana life sciences firms

February 10, 2014
J.K. Wall
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
More

Falling reimbursements force Roche to innovateRestricted Content

February 8, 2014
J.K. Wall
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If what you stated is true, then this article is entirely inaccurate. "State sells bonds" is same as "State borrows money". Supposedly the company will "pay for them". But since we are paying the company, we are still paying for this road with borrowed money, even though the state has $2 billion in the bank.

  2. Andrew hit the nail on the head. AMTRAK provides terrible service and that is why the state has found a contractor to improve the service. More trips, on-time performance, better times, cleanliness and adequate or better restrooms. WI-FI and food service will also be provided. Transit from outlying areas will also be provided. I wouldn't take it the way it is but with the above services and marketing of the service,ridership will improve and more folks will explore Indy and may even want to move here.

  3. They could take the property using eminent domain and save money by not paying the church or building a soccer field and a new driveway. Ctrwd has monthly meetings open to all customers of the district. The meetings are listed and if the customers really cared that much they would show. Ctrwd works hard in every way they can to make sure the customer is put first. Overflows damage the surrounding environment and cost a lot of money every year. There have been many upgrades done through the years to help not send flow to Carmel. Even with the upgrades ctrwd cannot always keep up. I understand how a storage tank could be an eye sore, but has anyone thought to look at other lift stations or storage tanks. Most lift stations are right in the middle of neighborhoods. Some close to schools and soccer fields, and some right in back yards, or at least next to a back yard. We all have to work together to come up with a proper solution. The proposed solution by ctrwd is the best one offered so far.

  4. Fox has comments from several people that seem to have some inside information. I would refer to their website. Changed my whole opionion of this story.

  5. This place is great! I'm piggy backing and saying the Cobb salad is great. But the ribs are awesome. $6.49 for ribs and 2 sides?! They're delicious. If you work downtown, head over there.

ADVERTISEMENT